PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Leaf extracts and hoslundin induced apoptosis in human hepatoma (HepG2) and breast cancer (MDA-MB-231) cell lines [PMID:36076500]
Leaf essential oil (110 and 220 mg/kg) significantly reduced fasting blood glucose levels in alloxan-induced diabetic rats [PMID:25137031]
Ethanol leaf extract demonstrated antioxidant and hepatoprotective activity [PMID:36381189]
Chloroform extract of the dried root produced 60% protection against leptazol-induced convulsion and potentiated phenobarbitone sleeping time [PMID:10441785]
Rootbark extracts showed antimalarial activity against the multidrug resistant K1 strain of Plasmodium falciparum [PMID:2236289]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36076500 (2022) — Fractions of Hoslundia opposita Vahl and hoslundin induced apoptosis in human cancer cells via mitochondrial-dependent reactive oxygen species (ROS) generation. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 2.PMID: 38886717 (2024) — Hoslundia opposita vahl; a potential source of bioactive compounds with antioxidant and antibiofilm activity for wound healing. · BMC complementary medicine and therapies
- 3.PMID: 18780245 (2008) — Bioactive compounds from Lippia javanica and Hoslundia opposita. · Natural product research
- 4.PMID: 22022167 (2011) — Acaricidal effect of an isolate from Hoslundia opposita vahl against Amblyomma variegatum (Acari: Ixodidae). · Pharmacognosy research
- 5.PMID: 28092425